Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 9Neoplasm Metastasis 7Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Tongue Neoplasms 1Thymoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Neoplasms 1Hypoxia 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Gliosarcoma 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma × NVP-BKM120 × Clear all
NCT02301364 2017-10-19

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
4 enrolled 11 charts
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡